T
Todd Belanger
Researcher at Pfizer
Publications - 6
Citations - 380
Todd Belanger is an academic researcher from Pfizer. The author has contributed to research in topics: Internal medicine & Pneumococcal conjugate vaccine. The author has an hindex of 2, co-authored 3 publications receiving 17 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Emmanuel B. Walter,Kawsar R. Talaat,Charu Sabharwal,Alejandra Gurtman,Stephen Lockhart,Grant Paulsen,Elizabeth D. Barnett,Flor M. Munoz,Yvonne Maldonado,Barbara A. Pahud,Joseph B. Domachowske,Eric A. F. Simões,Uzma N. Sarwar,Nicholas Kitchin,Luke Cunliffe,Pablo Rojo,Ernest Kuchar,Mika Rämet,Iona Munjal,John L. Perez,Robert W. Frenck,Eleni Lagkadinou,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Susan Mather,Todd Belanger,David K. C. Cooper,Özlem Türeci,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +33 more
TL;DR: A phase 1, dose-finding study and an ongoing phase 2-3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6 months to 11 years of age.
Journal ArticleDOI
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial
Masanari Shiramoto,Shin Irie,Christine Juergens,Masako Yamaji,Satoshi Tamai,Masakazu Aizawa,Todd Belanger,William C. Gruber,Daniel A. Scott,Beate Schmoele-Thoma +9 more
TL;DR: In conclusion, PCV13 elicited robust immune responses in the Japanese study population and the unanticipated higher immune responses observed in the older age group in theJapanese study are of interest and of potential benefit given the higher incidence of pneumococcal disease in older adults.
Journal ArticleDOI
Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
Kevin Cannon,Jose Cardona,Kari Yacisin,Allison Thompson,Todd Belanger,Dung Yang Lee,Yahong Peng,Lisa Moyer,John Ginis,William C. Gruber,Daniel A. Scott,Wendy J. Watson +11 more
TL;DR: This paper evaluated coadministration of 20-valent pneumococcal conjugate vaccine (PCV20) and an adjuvanted quadrivalent inactivated influenza vaccine (QIV).
Journal ArticleDOI
1337. Development, Maintenance, and Application of Opsonophagocytic Assays to Measure Functional Antibody Responses to Support a 20 Valent Pneumococcal Conjugate Vaccine
Ingrid L. Scully,Mark Cutler,Seema S Gangolli,Todd Belanger,David A. Cooper,Thomas R. Jones,Andrew McKeen,Charles Tan,Wendy Watson,Annaliesa S. Anderson,Kathrin U. Jansen,Michael W. Pride +11 more
TL;DR: Maintenance and careful monitoring of high-quality assays to measure functional antibody responses, such as OPAs, is critical for the delivery of reliable serological data to support the advancement of pneumococcal vaccine programs.
Journal ArticleDOI
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
Charu Sabharwal,Vani Sundaraiyer,Yahong Peng,Lisa Moyer,Todd Belanger,Bradford D. Gessner,Luis Jodar,Kathrin U. Jansen,William C. Gruber,Daniel A. Scott,Wendy J. Watson +10 more
TL;DR: In this article , the immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adults with chronic medical conditions or smoking that place them at increased risk of developing pneumonia was analyzed.